v3.25.1

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 210,629	$ 80,235
Available-for-sale securities	96,289	68,685
Prepaid expenses and other current assets	6,491	8,382
Total current assets	313,409	157,302
Non-current assets:
Operating lease, right-of-use assets	23,720	24,295
Property and equipment, net	4,483	4,747
Other non-current assets	319	366
Restricted cash	1,973	1,952
Total non-current assets	30,495	31,360
Total assets	343,904	188,662
Current liabilities:
Accounts payable	6,439	4,237
Accrued expenses and other current liabilities	14,576	19,852
Operating lease liabilities	1,868	1,787
Finance lease liabilities	1,096	1,231
Derivative liabilities	4,800	3,150
Total current liabilities	28,779	30,257
Non-current liabilities:
Operating lease liabilities, excluding current portion	20,662	21,159
Total non-current liabilities	20,662	21,159
Total liabilities	49,441	51,416
Commitments and contingencies (Note 9)
Stockholders' equity:
Preferred stock, $0.001 par value - 10,000,000 shares authorized; no shares issued or outstanding at March 31, 2025 and December 31, 2024
Common stock, $0.001 par value - 120,000,000 shares authorized; 77,492,959 and 40,468,141 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	77	40
Additional paid-in capital	1,117,116	920,609
Accumulated other comprehensive income	2	47
Accumulated deficit	(822,732)	(783,450)
Total stockholders’ equity	294,463	137,246
Total liabilities and stockholders’ equity	$ 343,904	$ 188,662

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Solid Biosciences Inc. 10-Q